TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20434403
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical therapy alone
Study: 23296149
Drug: Anti-CD25 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD25 monoclonal antibody (mAb) therapy
Study: 9827976
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral r‐metHuG‐CSF (filgrastim) administered as a viscous mouthrinse (carboxymethylcellulose 2%, oleum citrii) 4 x 120 microg/day from days 10 to 16.
Study: 9827976
Drug: Topical oral
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oral r‐metHuG‐CSF (filgrastim)
Study: 7986112
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with increased dose intensity
Study: 29531839
Drug: Adjuvant/neoadjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant/neoadjuvant chemotherapy
Study: 7986112
Drug: Standard adjuvant/neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant/neoadjuvant chemotherapy regimens
Study: 2506834
Drug: Intraportal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal chemotherapy with 30 mg of Mitomycin-C (in 3 doses) and 5 mg/kg/day of 5-FU (1985-1986) or 3 mg/kg/day of 5-FU (1987-1988)
Study: 2506834
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with the same doses of drugs injected into the peripheral vein
Study: 2506834
Drug: Intraportal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal chemotherapy with 5 mg/kg/day of 5-FU
Study: 2506834
Drug: Intraportal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraportal chemotherapy with 3 mg/kg/day of 5-FU
Study: 7304488
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of piperazine citrate administered twice within a 2-week period
Study: 7304488
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of piperazine citrate
Study: 30119098
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene and cosmetic products (toothpastes, dental tablets, mouthwashes, lip-balms, lipsticks)
Study: 29443750
Drug: roflumilast 500 μg
Normalized name: roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: roflumilast 500 μg once daily for 12 months
Study: 22154766
Drug: Metformin, 2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 2,000 mg/daily
Study: 14560075
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (primary health care treatment)
Study: 8227758
Drug: CBZ low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBZ low (15‐25 mumol/l)
Study: 8227758
Drug: CBZ high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBZ high (28‐40 mumol/l)
Study: 8227758
Drug: LI (0.6‐0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LI (0.6‐0.8 mumol/l)
Study: 28253878
Drug: Residents' interest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residents' interest in Kampo medicine
Study: 28253878
Drug: Perceived value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived value of learning Kampo medicine
Study: 28253878
Drug: Desire to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desire to learn Kampo medicine
Study: 28253878
Drug: Integration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integration of Western and Kampo medicine
Study: 28253878
Drug: Prescription of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription of Kampo medicine
Study: 26448147
Drug: IL–1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL–1 receptor antagonist IL‐1Ra (anakinra)
Study: 21168369
Drug: AS03(A) adjuvanted
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A) adjuvanted vaccine (3.75 μg of haemagglutinin)
Study: 21168369
Drug: Whole-virion vaccine
Normalized name: Whole-Virion Inactivated SARS-CoV-2 Vaccine
DrugBank: BBV152 (DB15847)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-virion vaccine (7.5 μg of haemagglutinin)
Study: 19298916
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution alone; control group, n = 128
Study: 4069863
Drug: Methylphenidate 5
Normalized name: dexmethylphenidate 5.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 5 mg
Study: 15896352
Drug: Methylphenidate 10
Normalized name: dexmethylphenidate 10.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 10 mg
Study: 3599565
Drug: Methylphenidate 15
Normalized name: METHYLPHENIDATE 15MG/9HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 15 mg
Study: 8188554
Drug: Follow-up dose
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up dose based on trial-phase data
Study: 3499456
Drug: Propafenone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (2 mg/kg body weight)
Study: 31978372
Drug: Conventional obesity
Normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional obesity treatment
Study: 28916667
Drug: IVMT (mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVMT (mechanical thrombectomy combined with intravenous thrombolysis)
Study: 28916667
Drug: IVT (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVT (intravenous thrombolysis)
Study: 23930638
Drug: Monitoring without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monitoring without further treatment (Control)
Study: 15180756
Drug: Omalizumab (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (at least 0.016 mg/kg/IgE (IU/ml) every 4 weeks for 12 months)
Study: 11871867
Drug: Treatment options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment options for pruritus in cancer patients; specific interventions not detailed.
Study: 8302503
Drug: Weekly one
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly one hour exercise classes supervised by a physiotherapist
Study: 30113209
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor intervention (15-minute program: stroking peri‐oral structures for 5 minutes, tongue exercises for 5 minutes, non‐nutritive sucking for 5 minutes, administered once daily for 10 days)
Study: 30113209
Drug: Oral sensorimotor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sensorimotor intervention
Study: 21600388
Drug: Oral B(12)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B(12) 1000 μg daily for 90 days
Study: 21600388
Drug: IM B(12)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM B(12) 1000 μg in 9 injections over 3 months
Study: 19457640
Drug: Dehydrated cell
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydrated cell fraction (DCF) high-dose 120mg
Study: 19457640
Drug: Dehydrated cell
Normalized name: Dehydrated Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydrated cell fraction (DCF) low-dose 5mg
Study: 11207509
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg on-demand therapy
Study: 11207509
Drug: Placebo on-demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on-demand therapy
Study: 11207509
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg and Placebo
Study: 30266677
Drug: Intermediate-dose cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intermediate-dose cytarabine (ID-AraC) plus G-CSF
Study: 26738812
Drug: PF-03049423 6
Normalized name: FERMENT COMPLEX 6/PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03049423 6 mg
Study: 23340738
Drug: Bendamustine 100
Normalized name: bendamustine 100 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine 100 mg/m² on days 1 and 2 of a 4-week cycle
Study: 23340738
Drug: Fludarabine 25
Normalized name: fludarabine 25 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 25 mg/m² on days 1 to 5 every 4 weeks
Study: 19526589
Drug: Temsirolimus (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (25 mg intravenously weekly)
Study: 19229667
Drug: Interferon-alpha (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (3 million units subcutaneously three times weekly, escalating to 18 MU)
Study: 16735934
Drug: lasofoxifene 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: lasofoxifene 0.25 mg/day
Study: 16735934
Drug: lasofoxifene 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: lasofoxifene 1.0 mg/day
Study: 11331428
Drug: Sibutramine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine (30 mg)
Study: 7919465
Drug: Natural IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural IFN beta (Frone) administered by intramuscular injection at a dosage of 5 Million Units (MU)/m2 three times weekly for six months
Study: 7919465
Drug: Natural IFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural IFN beta (Frone) administered by intramuscular injection
Study: 21345600
Drug: 3.6% garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6% garlic treatment group
Study: 21345600
Drug: 0% garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% garlic treatment group
Study: 21345600
Drug: 1.8% garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8% garlic treatment group
Study: 16339606
Drug: Itraconazole oral
Normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution (2.5 mg/kg twice daily)
Study: 16339606
Drug: Fluconazole oral
Normalized name: fluconazole Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole oral solution or capsules (400 mg daily)
Study: 12580982
Drug: nelfinavir/ritonavir 2,000/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: nelfinavir/ritonavir 2,000/200 mg with a full breakfast
Study: 12580982
Drug: nelfinavir/ritonavir 2,000/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: nelfinavir/ritonavir 2,000/400 mg with a full breakfast
Study: 12580982
Drug: nelfinavir/ritonavir 2,500/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: nelfinavir/ritonavir 2,500/200 mg with a full breakfast
Study: 10951826
Drug: Carvedilol (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (initial dose 12.5 mg, increased weekly to 75 mg/day)
Study: 7908570
Drug: Ethamsylate 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethamsylate 12.5 mg/kg intravenously within an hour of delivery, followed by doses at six-hourly intervals for four days (total dose 200 mg/kg)
Study: 7908570
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.1 mL/kg intravenously
Study: 7908570
Drug: Ethamsylate 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethamsylate 12.5 mg/kg intravenously
Study: 29534382
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided quadratus lumborum block with 30 ml 0.33% ropivacaine
Study: 23760393
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (16 sessions)
Study: 23760393
Drug: Escitalopram oxalate
Normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram oxalate (10-20 mg/d)
Study: 10816183
Drug: Nefazodone (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (maximal dose, 600 mg per day)
Study: 10816183
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Nefazodone + Cognitive behavioral-analysis system of psychotherapy)
Study: 26694733
Drug: CE 0.45
Normalized name: Femtrace 0.45mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.45 mg/BZA 20 mg
Study: 26694733
Drug: CE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CE 0.625 mg/BZA 20 mg
Study: 22737979
Drug: Best practices
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practices primary care plus home-based occupational therapy (24 sessions over 2 years)
Study: 22737979
Drug: Best practices
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practices primary care plus home-based occupational therapy
Study: 9845803
Drug: ITF 296
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF 296 (oral solution)
Study: 9845803
Drug: ITF 296
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF 296 (immediate-release tablet)
Study: 9845803
Drug: ITF 296
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF 296 (intravenous infusion)
Study: 9845803
Drug: ITF 296
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF 296 (oral administration)
Study: 12401759
Drug: Insulin injection
Normalized name: diluent for insulin lispro and regular insulin INJECTION VIAL (ML)
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin injection
Study: 338412
Drug: Trasylol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trasylol administered before and after ERCP
Study: 30958014
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (COMB)
Study: 28467293
Drug: Belimumab 10
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Belimumab 10 mg/kg intravenous treatment (concurrent cohort)
Study: 26077267
Drug: Self-monitoring of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring of oral anticoagulation therapy (OAT)
Study: 19630546
Drug: Enhanced Treatment
Normalized name: Thera-M Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment (ET) walking intervention
Study: 19630546
Drug: Minimal Treatment
Normalized name: Minimally modified low density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Treatment (MT) walking intervention
Study: 8383012
Drug: pH adjusted
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pH adjusted mepivacaine (4 ml sodium bicarbonate added, final pH 7.31)
Study: 8383012
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (4 ml saline added, final pH 5.6)
Study: 3533546
Drug: Mexiletine (Mexitil‐Perlongets),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (Mexitil‐Perlongets), 360 mg b.i.d.
Study: 27707818
Drug: MAG-enriched oil
Normalized name: magnesium hydroxide / mineral oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAG-enriched oil (500 mg EPA/day and 300 mg DHA/day)
Study: 24949605
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose PMC (PMC4/0)
Study: 24949605
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose PEG (PEG4/0)
Study: 24949605
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose PMC (PMC2/2)
Study: 24949605
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose PEG (PEG3/1)
Study: 24949605
Drug: Split PMC
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Split PMC dose
Study: 22337905
Drug: Dexamethasone (DEX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (DEX; 1 mg)
Study: 20167180
Drug: Insulin detemir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin detemir, dosed once daily
Study: 20167180
Drug: Insulin glargine,
Normalized name: insulin glargine, human recombin. analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin glargine, dosed once daily
Study: 12578294
Drug: TPN with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN with 1 IU ml(‐1) of heparin (n = 35)
Study: 12578294
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin (n = 31)
Study: 7188378
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg zopiclone
Study: 7188378
Drug: 10.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg zopiclone
Study: 26062880
Drug: Dual treatment
Normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual treatment
Study: 21710405
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication (various neuroleptic medications)
Study: 19526753
Drug: Compound Astragalus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Astragalus Recipe (CAR)
Study: 12117080
Drug: Budesonide administered
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide administered by Turbuhaler (DPI)
Study: 12117080
Drug: Budesonide therapy
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide therapy
Study: 12117080
Drug: Pulmicort Respules
Normalized name: Pulmicort Respules
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pulmicort Respules (nebulized formulation)
Study: 19565392
Drug: Lee Silverman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lee Silverman Voice Treatment (LSVT)
Study: 8960734
Drug: Placebo (respiration)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (respiration) treatment
Study: 6122057
Drug: Oral amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amphotericin B and nystatin
Study: 25732163
Drug: Sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 37.5 mg per day until progression
Study: 22865498
Drug: 0.85 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.85 g/day eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) (low dose)
Study: 22865498
Drug: 3.4 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g/day EPA + DHA (high dose)
Study: 17472824
Drug: Trial preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial preparation of TMP/SMX 40/200 mg per 5-ml, oral suspension
Study: 17472824
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation of TMP/SMX 40/200 mg per 5-ml, oral suspension
Study: 9590144
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) given as 200 microg/m2/d SC starting one day after HD C/T until neutrophil recovery
Study: 9590144
Drug: High-dose cytarabine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cytarabine-containing chemotherapy (HD C/T) without G-CSF
Study: 2713211
Drug: Bromocriptine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (1.25 mg)
Study: 2713211
Drug: Lisuride (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride (0.1 mg)
Study: 2713211
Drug: Terguride (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terguride (0.25 mg)
Study: 12470401
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose insulin with glucose, potassium and amino acids
Study: 7543114
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of GH (3.15 +/- 0.27 IU daily)
Study: 7543114
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections of GH (3.15 +/- 0.27 IU daily)
Study: 330937
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg methylproscillaridin (MP)
Study: 25005784
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium citrate 150 mg twice daily
Study: 8584148
Drug: Ketamine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (6 micrograms/kg/min after a bolus dose of 60 micrograms/kg)
Study: 8584148
Drug: Alfentanil (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (0.6 microgram/kg/min after a bolus dose of 7 micrograms/kg)
Study: 8218755
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cisapride q.d.s.
Study: 31735500
Drug: ChAdOx1 85A
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 85A alone (low dose Starter Group, n=6)
Study: 30980618
Drug: cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream containing herbal mixture
Study: 30980618
Drug: arbutin cream
DrugBank: Arbutin (DB11217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: arbutin cream
Study: 27853882
Drug: hANP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hANP infusion
Study: 20030859
Drug: Western and
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western and Chinese medicine together (Group B)
Study: 20030859
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine only (Group A)